Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy. - Wikidata - wikimedia - TriplyDB

Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.

Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.

http://www.wikidata.org/entity/Q37325728

about

Therapeutic Effects of Phytochemicals and Medicinal Herbs on Chemotherapy-Induced Peripheral Neuropathy Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review Chemotherapy-induced neuropathies-a growing problem for patients and health care providers Lifestyle-Related Factors in the Self-Management of Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer: A Systematic Review.Targeting DNA repair pathways for cancer treatment: what's new?The prophylactic effects of a traditional Japanese medicine, goshajinkigan, on paclitaxel-induced peripheral neuropathy and its mechanism of action Herbal medicines for the treatment of cancer chemotherapy-induced side effects.Platinum-induced neurotoxicity and preventive strategies: past, present, and future Effects of goshajinkigan, hachimijiogan, and rokumigan on mechanical allodynia induced by Paclitaxel in mice Herbal medicines and chemotherapy induced peripheral neuropathy (CIPN): A critical literature review.[Chemotherapy-induced peripheral neuropathies: an integrative review of the literature].Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy.Preventive effect of oral goshajinkigan on chronic oxaliplatin-induced hypoesthesia in rats Hedyotis diffusa Willd overcomes 5-fluorouracil resistance in human colorectal cancer HCT-8/5-FU cells by downregulating the expression of P-glycoprotein and ATP-binding casette subfamily G member 2.Go-sha-jinki-Gan (GJG) ameliorates allodynia in chronic constriction injury-model mice via suppression of TNF-α expression in the spinal cord.An effective therapeutic approach for oxaliplatin-induced peripheral neuropathy using a combination therapy with goshajinkigan and bushi Meta-Analysis of Oxaliplatin-Based Chemotherapy Combined With Traditional Medicines for Colorectal Cancer: Contributions of Specific Plants to Tumor Response.Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial.Integrative Medicine for Relief of Nausea and Vomiting in the Treatment of Colorectal Cancer Using Oxaliplatin-Based Chemotherapy: A Systematic Review and Meta-Analysis.Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.Liu Jun Zi Tang-A Potential, Multi-Herbal Complementary Therapy for Chemotherapy-Induced Neurotoxicity.Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation.Kampo Medicines for Frailty in Locomotor Disease.A Systematic Review of Herbal Medicine for Chemotherapy Induced Peripheral Neuropathy.Medicinal herbs in the treatment of neuropathic pain: a review.Gosha-Jinki-Gan Recovers Spermatogenesis in Mice with Busulfan-Induced Aspermatogenesis

P2860

Q28075341-01CE9CEE-81E0-4E52-A2E7-FF87A69A7A25 Q28270819-46C33CB0-DA6F-4B55-92AF-80E847F38550 Q28818565-3DFDB557-4011-41B8-8B44-7C89C5DDEDA4 Q30234847-70DB9883-533C-4105-BB92-F6EE7F346235 Q34015040-5895C01C-12A0-49D0-8C70-40001E629E6F Q34252224-CB41098C-34D0-4AC6-A332-A03B1AE57546 Q35066654-71EBBA28-095D-4BD1-B3AF-02F3B6392954 Q35345734-32A528DD-9462-4FCF-90C9-7CC390050479 Q35402526-8EC56771-8F0A-46CA-9A5B-1190C960729E Q35596252-4EDA465A-0BC2-4DDA-94D8-24D70325FDE1 Q35636254-0F8D59F0-E5FF-4818-B50B-B452F4B353B6 Q35799385-9E141F19-AE27-4523-B062-1A474B1FC640 Q36226275-E70A62CB-C4EB-4E40-8F91-BA6105C698CE Q36254642-774DB03D-B38D-46EE-B54B-6760FDBFECA8 Q36335981-7BC9097F-CDAF-4BDF-A36E-462DBC0D447B Q37115784-AF706698-6749-448B-BABF-B16D62420FB1 Q37473168-E3E56530-6CB2-4652-B66C-6D4E9C306EB3 Q38562812-C80C8A93-6A6F-4618-AC66-A48ACC487D18 Q38708085-A79A8AA5-1CBB-4EB3-95EF-70614D01F967 Q38748971-49D1D4C3-B1E8-4E54-9B97-E5E1F4B030F1 Q41207847-E02CF928-E9FB-47D5-8C4D-D641FF2FC7E2 Q47184816-E61F0092-776F-4858-A51B-972BBD237F56 Q47767827-26A32B2B-8B00-4C23-9002-AFC11C707E0B Q52565989-F5635EBE-8059-4E48-A892-7C968F1A85E4 Q52633236-0C78D99A-A58F-4558-8D0B-9166CCBBEEC5 Q55261697-916EF254-48BD-41A8-BC49-5B65987B4D64 Q55334538-DA5F191F-C521-4D0B-A97E-1F2DAE4B0FF2 Q55352555-3631F244-223B-4E71-B211-81B4DAF19201 Q58766291-22466AE3-B964-4BC9-945E-C255294290A7

P2860

Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.

http://www.wikidata.org/entity/Q37325728

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Goshajinkigan oxaliplatin neur ...... xaliplatin‑induced neuropathy.

@en

Goshajinkigan oxaliplatin neur ...... xaliplatin‑induced neuropathy.

@nl

type

label

Goshajinkigan oxaliplatin neur ...... xaliplatin‑induced neuropathy.

@en

Goshajinkigan oxaliplatin neur ...... xaliplatin‑induced neuropathy.

@nl

prefLabel

Goshajinkigan oxaliplatin neur ...... xaliplatin‑induced neuropathy.

@en

Goshajinkigan oxaliplatin neur ...... xaliplatin‑induced neuropathy.

@nl

P1433

Q37325728-D32F2A2B-BBAC-40AE-A8E5-3003F2B4FF4A

P1476

Q37325728-DFCDBDDD-63C2-49A9-87D6-4976A6353DC0

P2093

Q37325728-09313E02-AC3F-4480-B8D7-6B647FFEDBD0

Q37325728-1EBC1661-71F1-479B-B990-2185C6F4AE92

Q37325728-4EB0D3EF-5F0D-467E-A936-7A38549E457D

Q37325728-50824B0E-88C6-4BD9-89B6-30393CA7D838

Q37325728-5FECD802-935A-4AC0-9C6E-C3464FEBEE72

Q37325728-699F1C2E-CF58-4F2E-843C-14B9B61A28C4

Q37325728-77EB1FF6-DF13-48A6-A389-701E3AEFE2EB

Q37325728-AA26EE62-79F0-40C4-8167-F087115354F8

Q37325728-B68CF1BB-2F91-4B90-B284-216907943D2C

Q37325728-C9DEEE24-89FA-4BE5-A7A4-EE4D60B2E61F

P2860

Q37325728-0E3E44A1-0479-4F58-A8FB-293CEF9C1405

Q37325728-16A04532-9856-4F13-A2E9-F34C1566A784

Q37325728-189DDF13-9160-4FFF-A643-FB9D5C511EFE

Q37325728-295C8721-29F4-477D-81DE-7A17FDE3B4FC

Q37325728-426B6024-0632-410E-BAE6-6DF12D732A88

Q37325728-4B792669-D534-4D43-9917-2BDEED7A4EF5

Q37325728-544B8EB1-FBB1-4106-8C06-1387B3B024AE

Q37325728-58B291D4-0584-4699-A3E0-46D7C1C2DB93

Q37325728-58C262DE-87C4-4743-9B9C-C899F6B94764

Q37325728-68DDCC7C-C118-40C7-A877-23E349D1ACB0

P2888

Q37325728-9C0673DD-27EE-4C3C-9E05-A727BB48AA88

P304

Q37325728-44B484A8-F190-41AA-BA10-3ED2257E0EE9

P31

Q37325728-DB4B337A-DC6F-4280-9400-E7C22264EB44

P356

Q37325728-5B7D5C8C-40D2-459A-9071-AF68449C1C47

P433

Q37325728-CABF38E2-3143-4F35-9EA7-1150F56F2C61

P478

Q37325728-5E6D981A-3F1B-4A2F-899E-2187563C0BA0

P577

Q37325728-060D05FE-99D4-418F-B560-54AAD9AA09FD

P5875

Q37325728-27765632-5F02-43D3-BB03-48BD25B97313

P698

Q37325728-11AF8D82-66B6-4BF5-AA91-973CF509E439

P921

Q37325728-519E9572-1B43-4023-843D-AF4E7A6DDACD

Q37325728-917CFA96-3BE5-4289-9C6E-4978E964F4FD

Q37325728-AC326FC6-3F4D-498F-973F-FB8413F98235

Q37325728-B26530BC-F3D1-4CCD-B796-492440A037C7

P932

Q37325728-6F13F8F5-F52A-4C72-84D0-9838D80E0F03

P356

S00280-013-2306-7

P1433

Cancer Chemotherapy and Pharmacology

P1476

Goshajinkigan oxaliplatin neur ...... xaliplatin‑induced neuropathy.

@en

P2093

Hideyuki Mishima

http://www.w3.org/2001/XMLSchema#string

Hiroshi Kojima

http://www.w3.org/2001/XMLSchema#string

Hiroyoshi Takemoto

http://www.w3.org/2001/XMLSchema#string

Junichi Sakamoto

http://www.w3.org/2001/XMLSchema#string

Mitsuo Shimada

http://www.w3.org/2001/XMLSchema#string

Mutsumi Fukunaga

http://www.w3.org/2001/XMLSchema#string

Naoki Nagata

http://www.w3.org/2001/XMLSchema#string

Satoshi Morita

http://www.w3.org/2001/XMLSchema#string

Taishi Hata

http://www.w3.org/2001/XMLSchema#string

Takanori Matsui

http://www.w3.org/2001/XMLSchema#string

P2860

Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer

Preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy: a placebo-controlled double-blind randomized phase II study (the GONE Study)

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Safety of oxaliplatin in the treatment of colorectal cancer.

Infusion of calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in colorectal cancer: a systematic review and meta-analysis.

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.

Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer.

Oxaliplatin-associated neuropathy: a review.

Therapy of chemotherapy-induced peripheral neuropathy.

Exodus of Kampo, traditional Japanese medicine, from the complementary and alternative medicines: is it time yet?

P2888

s00280-013-2306-7

P304

1283-1290

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-013-2306-7

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257754288

http://www.w3.org/2001/XMLSchema#string

P698

24121454

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

multicenter trial

P932

3834178

http://www.w3.org/2001/XMLSchema#string